Cytokine gene therapy for malignant glioma

Expert Opinion on Biological Therapy

Volumn 4, Issue 10, 2004, Pages 1609-1620

  Okada, Hideho ^a   Pollack, Ian F ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccine; Cytokine; Dendritic cells; Gene therapy; Glioma

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CYTOKINE;

ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; BRAIN TUMOR; CANCER INVASION; CERVICAL LYMPH NODE; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; EFFECTOR CELL; GENE THERAPY; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; MALIGNANT NEOPLASTIC DISEASE; PROGNOSIS; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; BONE MARROW TRANSPLANTATION; BRAIN; BRAIN NEOPLASMS; CANCER VACCINES; CELLS, CULTURED; CLINICAL TRIALS; CYTOKINES; DENDRITIC CELLS; GENE THERAPY; GLIOBLASTOMA; GLIOMA; HUMANS; INTERFERON-ALPHA; MICE; RATS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; VACCINATION;

EID: 5644291973     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.10.1609     Document Type: Review

References (104)

1. KLEIHUES P, CAVENEE WK: Pathology and Genetics of Tumours of the Nervous System. Kleihues P, Cavenee WK (Eds), International Agency for Research on Cancer, Lyon, France (2000).
2. ASHBY LS, SHAPIRO WR: Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults. Curr. Neurol. Neurosci. Rep. (2004) 4:211-217.
3. WEN PY, KESARI S: Malignant gliomas. Curr. Neurol. Neurosci. Rep. (2004) 4:218-227.
4. OKADA H, GIEZEMAN-SMITS KM, TAHARA H et al.: Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSV-TK tumor vaccine. Gene Ther. (1999) 6:219-226.
5. YU JS, BURWICK JA, DRANOFF G, BREAKEFIELD XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum. Gene Ther. (1997) 8:1065-1072.
6. + cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system. Proc. Natl. Acad. Sci. USA (1996)93:10399-10404.
7. FISCHER HG, REICHMANN G: Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J. Immunol. (2001) 166:2717-2726.
8. SUTER T, BIOLLAZ G, GATTO D et al.: The brain as an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation. Eur. J. Immunol. (2003) 33:2998-3006.
9. WALKER PR, CALZASCIA T, DE TRIBOLET N, DIETRICH PY: T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res. Brain Res. Rev. (2003) 42:97-122. This is one of the most comprehensive and well-written reviews of brain and brain tumour immunology.
10. MORFORD LA, ELLIOTT LH, CARLSON SL, BROOKS WH, ROSZMAN TL: T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J. Immunol. (1997) 159:4415-4425.
11. DIX AR, BROOKS WH, ROSZMAN TL, MORFORD LA: Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunol. (1999) 100:216-232.
12. WIKSTRAND CJ, FREDMAN P, SVENNERHOLM L, BIGNER DD: Detection of glioma-associated gangliosides GM2, GD2, GD3, 3′-isoLM1 3′,6′-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. Prog. Brain Res. (1994) 101:213-223.
13. HISHII M, NITTA T, ISHIDA H et al.: Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurg. (1995) 37:1160-1166.
14. YANG T, WITHAM TF, VILLA L et al.: Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res. (2002) 62:2583-2591.
15. UYTTENHOVE C, PILOTTE L, THEATE I et al.: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. (2003) 9:1269-1274.
16. WELLER M, FONTANA A: The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res. (1995) 21:128-151.
17. GORELIK L, FLAVELL RA: Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. (2002) 2:46-53.
18. LYNCH DH, RAMSDELL F, ALDERSON MR: Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today (1995) 16:569-574.
19. SAAS P, WALKER PR, HAHNE M et al.: Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. (1997) 99:1173-1178.
20. WALKER PR, SAAS P, DIETRICH PY: Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol. (1997) 158:4521-4524.
21. DIDENKO VV, NGO HN, MINCHEW C, BASKIN DS: Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J. Neurosurg. (2002) 96:580-584.
22. CHEN JJ, SUN Y, NABEL GJ: Regulation of the proinflammatory effects of Fas ligand (CD95L). Science (1998) 282:1714-1717.
23. WALKER PR, SAAS P, DIETRICH PY: Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol. (1998) 10:564-572.
24. DE VOS AF, VAN MEURS M, BROK HP et al.: Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J. Immunol. (2002) 169:5415-5423.
25. WALKER PR, CALZASCIA T, SCHNURIGER V et al.: The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J. Immunol. (2000) 165:3128-3135.
26. KRAKOWSKI ML, OWENS T: The central nervous system environment controls effector CD4+ T cell cytokine profile in experimental allergic encephalomyelitis. Eur. J. Immunol. (1997) 27:2840-2847.
27. ALBERT ML, DARNELL JC, BENDER A, FRANCISCO LM, BHARDWAJ DARNELL RB: Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. (1998) 4:1321-1324. This is a landmark study delineating a CTL-mediated autoimmune brain pathology.
28. WAKIMOTO H, ABE J, TSUNODA R, AOYAGI M, HIRAKAWA K, HAMADA H: Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res. (1996) 56:1828-1833.
29. NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. (1998) 4:328-332. DC-based vaccines demonstrated clinical responses in some melanoma patients.
30. NESTLE FO, BANCHEREAU J, HART D: Dendritic cells: on the move from bench to bedside. Nat. Med. (2001) 7:761-765.
31. OKADA H, TAHARA H, SHURIN MR et al.: Bone marrow derived dendritic cells pulsed with a tumor specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int. J. Cancer (1998) 78:196-201.
32. SIESJO P, VISSE E, SJOGREN HO: Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J. Immunother. (1996) 19:334-345.
33. ASHLEY DM, FAIOLA B, NAIR S, HALE LP, BIGNER DD, GILBOA E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. (1997) 186:1177-1182.
34. LIAU LM, BLACK KL, PRINS RM et al.: Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg. (1999) 90:1115-1124.
35. KIRKWOOD JM, BENDER C, AGARWALA S et al.: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J. Clin. Oncol. (2002) 20:3703-3718.
36. DRANOFF G: Cancer gene therapy: connecting basic research with clinical inquiry. [Review]. J. Clin. Oncol. (1998) 16:2548-2556.
37. CLICK RP, LICHTOR T, DE ZOETEN E, DESHMUKH P, COHEN EP: Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery (1999) 45:867-874.
38. SAMPATH P, HANES J, DIMECO F et al.: Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res. (1999) 59:2107-2114.
39. DRANOFF G: GM-CSF-secreting melanoma vaccines. Oncogene (2003) 22:3188-3192.
40. HORTON HM, ANDERSON D, HERNANDEZ P, BARNHART KM, NORMAN JA, PARKER SE: A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc. Natl. Acad. Sci. USA (1999) 96:1553-1558.
41. HIROISHI K, TUTING T, TAHARA H, LOTZE MT: Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models. Gene Ther. (1999) 6:1988-1994.
42. FERRANTINI M, GIOVARELLI M, MODESTI A et al.: IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J. Immunol. (1994) 153:4604-4615.
43. TAHARA H, ZITVOGEL L, STORKUS WJ et al.: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. (1995) 154:6466-6474.
44. OSAKI T, HASHIMOTO W, GAMBOTTO A et al.: Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther. (1999) 6:808-815.
45. LO CH, LEE SC, WU PY et al.: Antitumor and antimetastatic activity of IL-23. J. Immunol. (2003) 171:600-607.
46. YU JS, WHEELER CJ, ZELTZER PM et al.: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. (2001) 61:842-847.
47. YAMANAKA R, TSUCHIYA N, YAJIMA N et al.: Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J. Neurosurg. (2003) 99:746-753.
48. KIKUCHI T, AKASAKI Y, IRIE M, HOMMA S, ABE T, OHNO T: Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. (2001) 50:337-344.
49. INABA K, INABA M, ROMANI N et al.: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. (1992) 176:1693-1702.
50. SOBOL RE, FAKHRAI H, SHAWLER D et al.: Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. (1995) 2:164-167.
51. JADUS MR, CHEN Y, BOLDAJI MT et al.: Human U251MG glioma cells expressing the membrane form of macrophage colony-stimulating factor (mM-CSF) are killed by human monocytes in vitro and are rejected within immunodeficient mice via paraptosis that is associated with increased expression of three different heat shock proteins. Cancer Gene Ther. (2003) 10:411-420.
52. CHEN Y, DOUGLASS T, JEFFES EW et al.: Living T9 glioma cells expressing membrane macrophage colony-stimulating factor produce immediate tumor destruction by polymorphonuclear leukocytes and macrophages via a 'paraptosis'-induced pathway that promotes systemic immunity against intracranial T9 gliomas. Blood (2002) 100:1373-1380.
53. OKADA H, VILLA LA, ATTANUCCI J et al.: Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther. (2001) 8:1157-1166.
54. OKADA H, ATTANUCCI J, TAHARA H et al.: Characterization and transduction of a retroviral vector encoding human interleukin-4 and the Herpes simplex-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Ther. (2000) 7:486-494.
55. OKADA H, POLLACK IF, LOTZE MT et al.: Gene therapy of malignant gliomas: a Phase I study of IL4HSV-TK gene-modified autologous tumor to elicit an immune response (clinical protocol). Hum. Gene Ther. (2000) 11:637-653.
56. OKADA H, LIEBERMAN FS, EDINGTON HD et al.: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J. Neurooncol. (2003) 64:13-20.
57. OKADA H, BANCHEREAU J, LOTZE MT: Interleukin-4. In: The Cytokine Handbook. Thomson AW, Lotze MT (Eds), Elsevier Science, London, UK (2003):227-262.
58. CELLUZZI C, MAYORDOMO JI, STORKUS WJ, LOTZE MT, FALO LD: Peptide pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. (1996) 183:283-287.
59. ROSENZWAJG M, CAMUS S, GUIGON M, GLUCKMAN JC: The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells. Exp. Hematol. (1998) 26:63-72.
60. TEPPER RI, LEVINSON DA, STANGER BZ, CAMPOS-TORRES J, ABBAS AK, LEDER P: IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell (1990) 62:457-467.
61. RODOLFO M, ZILOCCHI C, ACCORNERO P, CAPPETTI B, ARIOLI I, COLOMBO MP: IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. J Immunol. (1999) 163:1923-1928.
62. STOPPACCIARO A, PAGLIA P, LOMBARDI L, PARMIANI G, BARONI C, COLOMBO MP: Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur. J. Immunol. (1997) 27:2375-2382.
63. NESTLE FO, FILGUEIRA L, NICKOLOFF BJ, BURG G: Human dermal dendritic cells process and present soluble protein antigens. J. Invest. Dermatol. (1998) 110:762-766.
64. DECHANET J, BRIOLAY J, RISSOAN MC et al.: IL-4 inhibits growth factor-stimulated rheumatoid synoviocyte proliferation by blocking the early phases of the cell cycle. J. Immunol. (1993) 151:4908-4917.
65. DE JONG EC, VIEIRA PL, KALINSKI P, KAPSENBERG ML: Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. J. Leukoc. Biol. (1999) 66:201-204.
66. HOCHREIN H, SHORTMAN K, VREMEC D, SCOTT B, HERTZOG P, O'KEEFFE M: Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J. Immunol. (2001) 166:5448-5455.
67. BIEDERMANN T, ZIMMERMANN S, HIMMELRICH H et al.: IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol. (2001) 2:1054-1060. Local, but not systemic, delivery of IL-4 at the site of antigen presentation induces type 1 T cell responses.
68. NISHIHORI H, TSUJI H, WANG H et al.: Participation of endogenously produced interferon gamma in interleukin 4-mediated tumor rejection. Hum. Gene Ther. (2000) 11:659-668.
69. GIEZEMAN-SMITS KM, OKADA H, BRISSETTE-STORKUS SC et al.: Cytokine gene therapy of gliomas: Induction of reactive CD4+ T cells by interleukin-4 transfected 9L gliosarcoma is essential for protective immunity. Cancer Res. (2000) 60:2449-2457.
70. KALINSKI P, HILKENS CM, WIERENGA EA, KAPSENBERG ML: T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. [Review]. Immunol. Today (1999) 20:561-567.
71. DUTTA T, SPENCE A, LAMPSON LA: Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains. J. Neurooncol. (2003) 64:31-44.
72. PHILLIPS LM, LAMPSON LA: Site-specific control of T cell traffic in the brain: T cell entry to brainstem versus hippocampus after local injection of IFN-gamma. J. Neuroimmunol. (1999) 96:218-227.
73. YU JS, WEI MX, CHIOCCA EA, MARTUZA RL, TEPPER RI: Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res. (1993) 53:3125-3128.
74. LICHTOR T, GLICK RP, KIM TS, HAND R, COHEN EP: Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J. Neurosurg. (1995) 83:1038-1044.
75. BISCHOFF JR, KIRN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274:373-376.
76. NATSUME A, MIZUNO M, RYUKE Y, YOSHIDA J: Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther. (1999) 6:1626-1633.
77. YOSHIDA J, MIZUNO M, FUJII M et al.: Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum. Gene Ther. (2004) 15:77-86.
78. BENEDETTI S, BRUZZONE MG, POLLO B et al.: Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. Cancer Res. (1999) 59:645-652.
79. LIU Y, EHTESHAM M, SAMOTO K et al.: in situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther. (2002) 9:9-15.
80. TJUVAJEV J, GANSBACHER B, DESAI R et al.: RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res. (1995) 55:1902-1910.
81. ANDREANSKY S, HE B, VAN COTT J et al.: Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. (1998) 5:121-130.
82. ABOODY KS, BROWN A, RAINOV NG et al.: Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl Acad. Sci. USA (2000) 97:12846-12851. NSCs migrate towards intracranial gliomas.
83. BENEDETTI S, PIROLA B, POLLO B et al.: Gene therapy of experimental brain tumors using neural progenitor cells. Nat. Med. (2000) 6:447-450.
84. EHTESHAM M, KABOS P, KABOSOVA A, NEUMAN T, BLACK KL, YU JS: The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res. (2002) 62:5657-5663. This study proposes an attractive application of NSCs for the treatment of gliomas.
85. EHTESHAM M, KABOS P, GUTIERREZ MA et al.: Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. (2002) 62:7170-7174.
86. GAGE FH: Mammalian neural stem cells. [Review]. Science (2000) 287:1433-1438.
87. ROBERTSON JA: Ethics and policy in embryonic stem cell research. Kennedy Inst. Ethics J. (1999) 9:109-136.
88. LEE J, ELKAHLOUN AG, MESSINA SA et al.: Cellular and genetic characterization of human adult bone marrow-derived neural stem-like cells: a potential antiglioma cellular vector. Cancer Res. (2003) 63:8877-8889.
89. KABOS P, EHTESHAM M, KABOSOVA A, BLACK KL, YU JS: Generation of neural progenitor cells from whole adult bone marrow. Exp. Neurol. (2002) 178:288-293.
90. OKADA H, TSUGAWA T, SATO H et al.: Delivery of interferon-alpha transfected DCs into central nervous system tumors enhances the anti-tumor efficacy of peripheral peptide-based vaccines. Cancer Res. (2004) 64(16):5830-5838. This study demonstrates that IFN-transfected DCs can promote cross-presentation of brain tumour antigens systemically.
91. TSUGAWA T, KUWASHIMA N, SATO H et al.: Sequential delivery of interferon-gene and DCs to intracranial gliomas promotes an effective anti-tumor response. Gene Ther. (2004) (In Press).
92. ROUARD H, LEON A, KLONJKOWSKI B et al.: Adenoviral transduction of human 'clinical grade' immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity. J. Immunol. Methods (2000) 241:69-81.
93. DEWEY RA, MORRISSEY G, COWSILL CM et al.: Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat. Med. (1999) 5:1256-1263.
94. MONTOYA M, SCHIAVONI G, MATTEI F et al.: Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood (2002) 99:3263-3271.
95. OPPMANN B, LESLEY R, BLOM B et al.: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 13:715-725.
96. CUA DJ, SHERLOCK J, CHEN Y et al.: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 421:744-748.
97. HARTMANN E, WOLLENBERG B, ROTHENFUSSER S et al.: Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. (2003) 63:6478-6487.
98. TOURKOVA IL, YURKOVETSKY ZR, GAMBOTTO A et al.: Increased function and survival of IL-15-transduced human dendritic cells are mediated by upregulation of IL-15RaIpHa and Bcl-2. J. Leukoc. Biol. (2002) 72:1037-1045.
99. COSMI L, LIOTTA F, ANGELI R et al.: Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood (2004) 103(8):3117-3121.
100. MASLINSKA D: The cytokine network and interleukin-15 (IL-15) in brain development. Folia Neuropathol. (2001) 39:43-47.
101. BLANCO-JEREZ C, PLAZA JF, MASJUAN J, ORENSANZ LM, ALVAREZ-CERMENO JC: Increased levels of IL-15 mRNA in relapsing-remitting multiple sclerosis attacks. J. Neuroimmunol. (2002) 128:90-94.
102. WHEELER CJ, BLACK KL, LIU G et al.: Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J. Immunol. (2003) 171:4927-4933.
103. TRINCHIERI G, PFLANZ S, KASTELEIN RA: The IL-12 family of heterodimeric cytokines. New players in the regulation of T cell responses. Immunity (2003) 19:641-644.
104. PFLANZ S, TIMANS JC, CHEUNG J et al.: IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity (2002) 16:779-790.